Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for FDC
Revenue projections for FDC



Financial Ratios:

currentRatio 0.00000
forwardPE 0.00000
debtToEquity 0.92800
earningsGrowth 0.01900
revenueGrowth 0.01600
grossMargins 0.66268
operatingMargins 0.19346
trailingEps 16.53000
forwardEps 23.30000

FDC's negative gross and operating margins suggest that the company is experiencing losses at both the production and operational levels. This could point to inefficiencies or declining demand for its products.
FDC's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for FDC's financial performance.

Recommendation changes over time:

Recommendations trend for FDC
Recommendations trend for FDC


The recent buy bias from analysts suggests FDC is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, FDC appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.